Merck’s Keytruda lung cancer drug just produced successful results in a Phase II/III trial, and investors were loving it. Shares of Merck headed higher after Keytruda was revealed to demonstrate better survival rates when compared to traditional chemotherapy treatment in patients with previously untreated lung cancer. The trial was restricted only to patients with at … Continue reading “Positive Lung Cancer Trial Results Send Merck (MRK) Shares Higher”
